Consumer sentiment in the US has fallen to a near-record low due to the ongoing federal government shutdown, raising concerns about the economy's future. The latest survey shows widespread anxiety among consumers.
With the fantasy football playoffs approaching, discover the must-start players and those to avoid in Week 10. Key insights on quarterbacks, running backs, receivers, and tight ends that could make or break your season!
Nintendo Co. sees a significant stock increase after boosting its Switch 2 sales outlook to 19 million units ahead of the holiday season, signaling strong market confidence.
Palantir Technologies is experiencing explosive growth in its AI platform, yet its stock has taken a hit, falling 9%. Analysts are divided on its valuation, with some seeing it as overvalued despite record revenues. What does this mean for investors?
In the first elections of Trump's second term, voters express widespread dissatisfaction with his leadership and both political parties, highlighting economic concerns and a grim national outlook.
Asian stocks experienced a rise driven by optimism from the U.S.-China trade truce and increased AI spending. However, uncertainty looms over the longevity of the truce as investors reassess their strategies.
Over 40 million Americans relying on SNAP benefits face uncertainty after a federal judge's ruling. With a government shutdown in effect, food banks warn of a looming public health crisis as benefits may be delayed.
Stock futures climbed on Thursday night as investors reacted to strong earnings from Amazon and Apple. With Amazon's cloud revenue soaring and Apple's fiscal forecasts shining, optimism is high despite recent market fluctuations.
Chipotle's shares dropped more than 15% in after-hours trading after the chain slashed its sales forecast for the third consecutive quarter, citing ongoing macroeconomic challenges affecting consumer behavior.
Eli Lilly's third-quarter results exceeded estimates, driven by strong demand for Zepbound and Mounjaro. The company raised its revenue forecast, fueling a 5% rise in shares. Discover how Eli Lilly is maintaining its lead in the competitive obesity drug market.